1. This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More.

Ampligen - Hemispherx Biopharma announcement re ME/CFS

Discussion in 'BioMedical ME/CFS News' started by Sly Saint, Nov 24, 2017.

  1. Sly Saint

    Sly Saint Senior Member (Voting Rights)

    Messages:
    220
    Likes Received:
    1,542
    "PHILADELPHIA, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American:HEB) announced today its financial results for the third quarter ended September 30, 2017."

    "We have secured our first country approval for Ampligen® in ME/CFS and we expect several more in the coming years."

    "Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)."

    http://ir.hemispherx.net/profiles/i...ryID=86477&BzID=2265&g=980&Nav=0&LangID=1&s=0

    eta: see also http://scr.zacks.com/News/Press-Rel...ause-A-Turnaround-For-Hemispherx/default.aspx
     
  2. Sly Saint

    Sly Saint Senior Member (Voting Rights)

    Messages:
    220
    Likes Received:
    1,542


    "The new management team has achieved several recent milestones including:

    1. The first shipment of Ampligen delivered for sale in Europe utilizing the Early Access Program (EAP)

    2. EAP in Europe extended to pancreatic cancer patients beginning in the Netherlands

    3. FDA approval to increase price for US-based Ampligen cost recovery program

    4. Initiated a commercial scale production plan with our primary contract manufacturer to meet anticipated future demands in both international programs as well as domestic programs

    5. Collaboration with Millions Missing Canada to bring medication to Canadians for ME/CFS

    6. Completed an intranasal human safety study of Ampligen plus FluMist® and has commenced full data analysis."

    http://livetrades.tv/hemispherx-heb...-multi-billion-dollar-immuno-oncology-market/
     
    Sue, Inara, Little Bluestem and 5 others like this.

Share This Page